OncoMatch/Clinical Trials/NCT07151040
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Is NCT07151040 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies TH9619 for solid tumor.
Treatment: TH9619 — This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Colorectal Cancer
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Carcinoma
Gastric Cancer
Disease stage
Metastatic disease required
Prior therapy
Must have received: cytotoxic chemotherapy — metastatic/unresectable
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify